Biofrontera quadruples shareholder base and increases trading volume

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Leverkusen, Germany, - Biofrontera (DSE: B8F) announces that its
shareholder base has grown four-fold to about 1200 shareholders since
the beginning of the year. At the same time the liquidity of the
stock has greatly increased. Compared to the last months of the
preceding year the recent daily trading was 10 to 20 times higher.
Trading volumes in the five-digit range, which were exceptional last
year, are now common. Even the trading of more than 100,000 shares
per day has occasionally occurred without major movements of the
stock price.

With the three capital increases that Biofrontera has, in spite of
the difficult market conditions, been able to close this year, the
company's share number increased to 7.6 mln. In parallel, the
free-float grew to over 60%, such that the majority of the shares is
now held by small funds and private investors.

The market launch of the medical cosmetic Belixos®, occurring at the
largest European dermatology congress at the beginning of October,
has been very successful. In the meantime the direct marketing
through Biofrontera's dermatology sales force was initiated. Belixos®
is a cream with purely herbal ingredients which was specifically
developed for the daily care of irritated and inflamed skin. Due to
the initial concentration of the marketing efforts on selected
competence centers the users of the cream will obtain expert advice.
This has led to very positive resonance on the daily use of Belixos®
cream that has particularly been expressed by patients with skin
diseases like atopic dermatitis or psoriasis.

With the ongoing data analysis of the last pivotal trial with BF-200
ALA for the treatment of actinic keratosis the filing for the
marketing authorization with the EMEA in Q3 2010 comes close.
Short-term, Biofrontera anticipates forming license and distribution
agreements with strong international partners focusing on the
dermatology market.

"The significant expansion of the shareholder base and the increased
liquidity of the stock reflect the positive development of
Biofrontera's business. They serve as important benchmarks, which
find strong attention when addressing investment groups," commented
Werner Pehlemann, CFO of Biofrontera AG, the development.

About Biofrontera AG
Biofrontera AG is specialized in the development of pharmaceutical
products in the area of dermatology. The company is characterized by
a broad, relatively close to the market product portfolio.
Biofrontera is listed in the regulated market of the Düsseldorf stock
exchange under the symbol B8F and the ISIN DE0006046113.

This press release contains forward-looking statements based on the
currently held beliefs and assumptions of the management of
Biofrontera AG, which are expressed in good faith and, in their
opinion, reasonable. Forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause the
assumptions expressed or implied in this press release to be faulty.
Given these risks, uncertainties and other factors, recipients of
this document are cautioned not to place undue reliance on the
forward-looking statements. Biofrontera AG disclaims any obligation
to update these forward-looking statements to reflect future events
or developments.

For further information please contact:

Anke zur Mühlen
Corporate Communication

+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
a.zurmuehlen@biofrontera.com

Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany

--- End of Message ---

Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany

WKN: 604611;
ISIN: DE0006046113;
Listed: Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse
München,
Freiverkehr in Börse Stuttgart, Open Market (Freiverkehr) in
Frankfurter Wertpapierbörse,
Regulierter Markt in Börse Düsseldorf;
Copyright © Hugin AS 2009. All rights reserved.